Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1436

1.

Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study.

Jujić A, Atabaki-Pasdar N, Nilsson PM, Almgren P, Hakaste L, Tuomi T, Berglund LM, Franks PW, Holst JJ, Prasad RB, Torekov SS, Ravassa S, Díez J, Persson M, Melander O, Gomez MF, Groop L, Ahlqvist E, Magnusson M.

Diabetologia. 2020 Jan 23. doi: 10.1007/s00125-020-05093-9. [Epub ahead of print]

PMID:
31974732
2.

Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis.

Suppli MP, Bagger JI, Lund A, Demant M, van Hall G, Strandberg C, Kønig MJ, Rigbolt K, Langhoff JL, Wewer Albrechtsen NJ, Holst JJ, Vilsbøll T, Knop FK.

Diabetes. 2020 Jan 23. pii: db190715. doi: 10.2337/db19-0715. [Epub ahead of print]

PMID:
31974144
3.

Consumption of nutrients and insulin resistance suppress markers of bone turnover in subjects with abdominal obesity.

Fuglsang-Nielsen R, Rakvaag E, Vestergaard P, Hartmann B, Holst JJ, Hermansen K, Gregersen S, Starup-Linde J.

Bone. 2020 Jan 15;133:115230. doi: 10.1016/j.bone.2020.115230. [Epub ahead of print]

PMID:
31954199
4.

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.

Bergmann NC, Gasbjerg LS, Heimbürger SM, Krogh LSL, Dela F, Hartmann B, Holst JJ, Jessen L, Christensen MB, Vilsbøll T, Lund A, Knop FK.

Diabetes Care. 2020 Jan 16. pii: dc190578. doi: 10.2337/dc19-0578. [Epub ahead of print]

PMID:
31949084
5.

Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass.

Øhrstrøm CC, Worm D, Kielgast UL, Holst JJ, Hansen DL.

Obes Surg. 2020 Jan 6. doi: 10.1007/s11695-020-04387-6. [Epub ahead of print]

PMID:
31907828
6.

Recent advances of GIP and future horizons.

Holst JJ, Rosenkilde MM.

Peptides. 2019 Dec 12:170230. doi: 10.1016/j.peptides.2019.170230. [Epub ahead of print] Review.

PMID:
31838219
7.

Postprandial dyslipidemia, hyperinsulinemia, and impaired gut peptides/bile acids in adolescents with obesity.

Higgins V, Asgari S, Hamilton JK, Wolska A, Remaley AT, Hartmann B, Holst JJ, Adeli K.

J Clin Endocrinol Metab. 2019 Dec 11. pii: dgz261. doi: 10.1210/clinem/dgz261. [Epub ahead of print]

PMID:
31825485
8.

Gastric Bypass with Different Biliopancreatic Limb Lengths Results in Similar Post-absorptive Metabolomics Profiles.

Jarak I, Pereira SS, Carvalho RA, Oliveira PF, Alves MG, Guimarães M, Wewer Albrechtsen NJ, Holst JJ, Nora M, Monteiro MP.

Obes Surg. 2019 Dec 10. doi: 10.1007/s11695-019-04294-5. [Epub ahead of print]

PMID:
31820408
9.

Incretin therapy for diabetes mellitus type 2.

Holst JJ.

Curr Opin Endocrinol Diabetes Obes. 2020 Feb;27(1):2-10. doi: 10.1097/MED.0000000000000516.

PMID:
31815785
10.

Habitual activity associates with lower fasting and greater glucose-induced GLP-1 response in men.

Janus C, Vistisen D, Amadid H, Witte DR, Lauritzen T, Brage S, Bjerregaard AL, Hansen T, Holst JJ, Jørgensen ME, Pedersen O, Færch K, Torekov S.

Endocr Connect. 2019 Dec 1. pii: EC-19-0408.R2. doi: 10.1530/EC-19-0408. [Epub ahead of print]

11.

Correction to: Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys.

Thomsen M, Holst JJ, Molander A, Linnet K, Ptito M, Fink-Jensen A.

Psychopharmacology (Berl). 2020 Jan;237(1):287. doi: 10.1007/s00213-019-05374-1.

PMID:
31768561
12.

Glucagon-like peptide 1 (GLP-1).

Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH.

Mol Metab. 2019 Dec;30:72-130. doi: 10.1016/j.molmet.2019.09.010. Epub 2019 Sep 30. Review.

13.

Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes.

Tharp WG, Gupta D, Sideleva O, Deacon CF, Holst JJ, Elahi D, Pratley RE.

Diabetes. 2020 Feb;69(2):146-157. doi: 10.2337/db18-1163. Epub 2019 Nov 22.

PMID:
31757794
14.

Intestinal sensing and handling of dietary lipids in gastric bypass-operated patients and matched controls.

Martinussen C, Dirksen C, Bojsen-Møller KN, Svane MS, Carlsson ER, Hartmann B, Clausen TR, Veedfald S, Kristiansen VB, Rehfeld JF, Hansen HS, Holst JJ, Madsbad S.

Am J Clin Nutr. 2020 Jan 1;111(1):28-41. doi: 10.1093/ajcn/nqz272.

PMID:
31742316
15.

Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People.

Shadid S, Abosi-Appeadu K, De Maertelaere AS, Defreyne J, Veldeman L, Holst JJ, Lapauw B, Vilsbøll T, T'Sjoen G.

Diabetes Care. 2020 Feb;43(2):411-417. doi: 10.2337/dc19-1061. Epub 2019 Nov 18.

PMID:
31740479
16.

In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients.

Fedorova TD, Knudsen K, Hartmann B, Holst JJ, Viborg Mortensen F, Krogh K, Borghammer P.

Neurogastroenterol Motil. 2019 Nov 12:e13759. doi: 10.1111/nmo.13759. [Epub ahead of print]

PMID:
31715652
17.

A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals.

Øhrstrøm CC, Hansen DL, Kielgast UL, Hartmann B, Holst JJ, Worm D.

Obes Surg. 2019 Nov 10. doi: 10.1007/s11695-019-04248-x. [Epub ahead of print]

PMID:
31709494
18.

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists.

Gasbjerg LS, Bergmann NC, Stensen S, Christensen MB, Rosenkilde MM, Holst JJ, Nauck M, Knop FK.

Peptides. 2019 Nov 3:170183. doi: 10.1016/j.peptides.2019.170183. [Epub ahead of print] Review.

PMID:
31693916
19.

Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications.

Holst JJ, Albrechtsen NJW, Rosenkilde MM, Deacon CF.

Compr Physiol. 2019 Sep 19;9(4):1339-1381. doi: 10.1002/cphy.c180013.

PMID:
31688969
20.

A Pilot Study Showing Acute Inhibitory Effect of GLP-1 on the Bone Resorption Marker CTX in Humans.

Nissen A, Marstrand S, Skov-Jeppesen K, Bremholm L, Hornum M, Andersen UB, Holst JJ, Rosenkilde MM, Hartmann B.

JBMR Plus. 2019 Aug 23;3(10):e10209. doi: 10.1002/jbm4.10209. eCollection 2019 Oct.

21.

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.

Jensen SBK, Lundgren JR, Janus C, Juhl CR, Olsen LM, Rosenkilde M, Holst JJ, Stallknecht BM, Madsbad S, Torekov SS.

BMJ Open. 2019 Nov 2;9(11):e031431. doi: 10.1136/bmjopen-2019-031431.

22.

Methods and Guidelines for Measurement of Glucagon in Plasma.

Holst JJ, Wewer Albrechtsen NJ.

Int J Mol Sci. 2019 Oct 30;20(21). pii: E5416. doi: 10.3390/ijms20215416. Review.

23.

No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects.

Nauck MA, Holle H, Kahle M, Tytko A, Deacon CF, Holst JJ, Meier JJ.

Peptides. 2019 Oct 25:170176. doi: 10.1016/j.peptides.2019.170176. [Epub ahead of print]

PMID:
31669136
24.

Glucose-dependent insulinotropic polypeptide is a pancreatic polypeptide secretagogue in humans.

Veedfald S, Vedtofte L, Skov-Jeppesen K, Deacon CF, Hartmann B, Vilsbøll T, Knop FK, Christensen MB, Holst JJ.

J Clin Endocrinol Metab. 2019 Oct 26. pii: dgz097. doi: 10.1210/clinem/dgz097. [Epub ahead of print]

PMID:
31665480
25.

Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes.

Jørgensen NB, Bojsen-Møller KN, Dirksen C, Martinussen C, Svane MS, Kristiansen VB, Holst JJ, Madsbad S.

Sci Rep. 2019 Oct 22;9(1):15154. doi: 10.1038/s41598-019-51516-y.

26.

Effects of Exercise Training and IL-6 Receptor Blockade on Gastric Emptying and GLP-1 Secretion in Obese Humans: Secondary Analyses From a Double Blind Randomized Clinical Trial.

Lehrskov LL, Christensen RH, Wedell-Neergaard AS, Legaard GE, Dorph E, Larsen MK, Henneberg M, Launbo N, Fagerlind SR, Seide SK, Nymand S, Ball M, Vinum N, Dahl C, Wewer Albrechtsen NJ, Holst JJ, Ried-Larsen M, Rosenmeier JB, Krogh-Madsen R, Karstoft K, Pedersen BK, Ellingsgaard H.

Front Physiol. 2019 Oct 4;10:1249. doi: 10.3389/fphys.2019.01249. eCollection 2019.

27.

GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2.

Gasbjerg LS, Hartmann B, Christensen MB, Lanng AR, Vilsbøll T, Jørgensen NR, Holst JJ, Rosenkilde MM, Knop FK.

Bone. 2020 Jan;130:115079. doi: 10.1016/j.bone.2019.115079. Epub 2019 Oct 14.

PMID:
31622777
28.

Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease.

Jørgensen MB, Idorn T, Rydahl C, Hansen HP, Bressendorff I, Brandi L, Wewer Albrechtsen NJ, van Hall G, Hartmann B, Holst JJ, Knop FK, Hornum M, Feldt-Rasmussen B.

J Clin Endocrinol Metab. 2020 Jan 1;105(1). pii: dgz048. doi: 10.1210/clinem/dgz048.

PMID:
31608934
29.

Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1.

Jepsen SL, Vestergaard ET, Larraufie P, Gribble FM, Reimann F, Jørgensen JOL, Holst JJ, Kuhre RE.

J Clin Endocrinol Metab. 2020 Jan 1;105(1). pii: dgz046. doi: 10.1210/clinem/dgz046.

PMID:
31608930
30.

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures.

Lundgren JR, Færch K, Witte DR, Jonsson AE, Pedersen O, Hansen T, Lauritzen T, Holst JJ, Vistisen D, Jørgensen ME, Torekov SS, Johansen NB.

Cardiovasc Diabetol. 2019 Oct 5;18(1):130. doi: 10.1186/s12933-019-0937-7.

31.

Effects of a High-Protein/Moderate-Carbohydrate Diet on Appetite, Gut Peptides, and Endocannabinoids-A Preview Study.

Tischmann L, Drummen M, Gatta-Cherifi B, Raben A, Fogelholm M, Hartmann B, Holst JJ, Matias I, Cota D, Mensink RP, Joris PJ, Westerterp-Plantenga MS, Adam TC.

Nutrients. 2019 Sep 21;11(10). pii: E2269. doi: 10.3390/nu11102269.

32.

Gluco-metabolic effects of oral and intravenous alcohol administration in men.

Lanng ARR, Gasbjerg LS, Bergmann NC, Bermann S, Helsted MM, Gillum MP, Hartmann B, Holst JJ, Vilsbøll T, Knop FK.

Endocr Connect. 2019 Sep 1. pii: EC-19-0317.R1. doi: 10.1530/EC-19-0317. [Epub ahead of print]

33.

Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice.

Jepsen SL, Grunddal KV, Wewer Albrechtsen NJ, Engelstoft MS, Gabe MBN, Jensen EP, Ørskov C, Poulsen SS, Rosenkilde MM, Pedersen J, Gribble FM, Reimann F, Deacon CF, Schwartz TW, Christ AD, Martin RE, Holst JJ.

Am J Physiol Endocrinol Metab. 2019 Dec 1;317(6):E1081-E1093. doi: 10.1152/ajpendo.00239.2019. Epub 2019 Sep 10.

PMID:
31503512
34.

Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass.

Iepsen EW, Zhang J, Hollensted M, Madsbad S, Hansen T, Holst JJ, Jørgensen NR, Holm JC, Torekov SS.

J Bone Miner Metab. 2020 Jan;38(1):117-125. doi: 10.1007/s00774-019-01034-8. Epub 2019 Aug 30.

PMID:
31471646
35.

Short-chain fatty acids and regulation of pancreatic endocrine secretion in mice.

Ørgaard A, Jepsen SL, Holst JJ.

Islets. 2019;11(5):103-111. doi: 10.1080/19382014.2019.1587976. Epub 2019 Aug 30.

36.

Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans.

Müller M, Hernández MAG, Goossens GH, Reijnders D, Holst JJ, Jocken JWE, van Eijk H, Canfora EE, Blaak EE.

Sci Rep. 2019 Aug 29;9(1):12515. doi: 10.1038/s41598-019-48775-0.

37.

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats.

Baldassano S, Gasbjerg LS, Kizilkaya HS, Rosenkilde MM, Holst JJ, Hartmann B.

Front Endocrinol (Lausanne). 2019 Aug 6;10:492. doi: 10.3389/fendo.2019.00492. eCollection 2019.

38.

Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity.

Dollerup OL, Trammell SAJ, Hartmann B, Holst JJ, Christensen B, Møller N, Gillum MP, Treebak JT, Jessen N.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):5703-5714. doi: 10.1210/jc.2019-01081.

PMID:
31390002
39.

The imprinted gene Delta like non-canonical notch ligand 1 (Dlk1) associates with obesity and triggers insulin resistance through inhibition of skeletal muscle glucose uptake.

Jensen CH, Kosmina R, Rydén M, Baun C, Hvidsten S, Andersen MS, Christensen LL, Gastaldelli A, Marraccini P, Arner P, Jørgensen CD, Laborda J, Holst JJ, Andersen DC.

EBioMedicine. 2019 Aug;46:368-380. doi: 10.1016/j.ebiom.2019.07.070. Epub 2019 Aug 3.

40.

A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial.

Skytte MJ, Samkani A, Petersen AD, Thomsen MN, Astrup A, Chabanova E, Frystyk J, Holst JJ, Thomsen HS, Madsbad S, Larsen TM, Haugaard SB, Krarup T.

Diabetologia. 2019 Nov;62(11):2066-2078. doi: 10.1007/s00125-019-4956-4. Epub 2019 Jul 23.

PMID:
31338545
41.

GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals.

Larsson M, Patrone C, von Euler M, Holst JJ, Nathanson D.

Cardiovasc Diabetol. 2019 Jul 15;18(1):91. doi: 10.1186/s12933-019-0896-z.

42.

Glucagon Receptor Signaling and Glucagon Resistance.

Janah L, Kjeldsen S, Galsgaard KD, Winther-Sørensen M, Stojanovska E, Pedersen J, Knop FK, Holst JJ, Wewer Albrechtsen NJ.

Int J Mol Sci. 2019 Jul 5;20(13). pii: E3314. doi: 10.3390/ijms20133314. Review.

43.

Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery.

Jorsal T, Wewer Albrechtsen NJ, Christensen MM, Mortensen B, Wandall E, Langholz E, Friis S, Worm D, Ørskov C, Støving RK, Andries A, Juhl CB, Sørensen F, Forman JL, Falkenhahn M, Musholt PB, Theis S, Larsen PJ, Holst JJ, Vrang N, Jelsing J, Vilsbøll T, Knop FK.

J Clin Endocrinol Metab. 2019 Dec 1;104(12):6403-6416. doi: 10.1210/jc.2019-00062.

PMID:
31276156
44.

Gastric Emptying and Distal Gastrectomy Independently Enhance Postprandial Glucagon-Like Peptide-1 Release After a Mixed Meal and Improve Glycemic Control in Subjects Having Undergone Pancreaticoduodenectomy.

Steiner E, Breuer R, Kazianka L, Wewalka M, Stimpfl T, Reiter B, Holst JJ, Miholic J.

Pancreas. 2019 Aug;48(7):953-957. doi: 10.1097/MPA.0000000000001361.

PMID:
31268979
45.

Pros and cons of Roux en-Y gastric bypass surgery in obese patients with type 2 diabetes.

Justinussen T, Madsbad S, Holst JJ, Bojsen-Møller KN.

Expert Rev Endocrinol Metab. 2019 Jul;14(4):243-257. doi: 10.1080/17446651.2019.1628639. Epub 2019 Jun 19.

PMID:
31215828
46.

The diurnal variation of bone formation is attenuated in adult patients with type 2 diabetes.

Hygum K, Starup-Linde JK, Harsløf T, Joergensen NR, Hartmann B, Holst JJ, Langdahl B.

Eur J Endocrinol. 2019 Jun 1. pii: EJE-19-0309.R1. doi: 10.1530/EJE-19-0309. [Epub ahead of print]

PMID:
31189129
47.

Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?

Holst JJ.

Lancet. 2019 Jul 6;394(10192):4-6. doi: 10.1016/S0140-6736(19)31350-9. Epub 2019 Jun 8. No abstract available.

PMID:
31186119
48.

Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study.

Behary P, Tharakan G, Alexiadou K, Johnson N, Wewer Albrechtsen NJ, Kenkre J, Cuenco J, Hope D, Anyiam O, Choudhury S, Alessimii H, Poddar A, Minnion J, Doyle C, Frost G, Le Roux C, Purkayastha S, Moorthy K, Dhillo W, Holst JJ, Ahmed AR, Prevost AT, Bloom SR, Tan TM.

Diabetes Care. 2019 Aug;42(8):1446-1453. doi: 10.2337/dc19-0449. Epub 2019 Jun 8.

49.

Fatty Liver Among Adolescent Offspring of Women With Type 1 Diabetes (the EPICOM Study).

Knorr S, Bytoft B, Lohse Z, Boisen AB, Clausen TD, Jensen RB, Damm P, Beck-Nielsen H, Holst JJ, Hartmann B, Møller HJ, Højlund K, Gravholt CH, Jensen DM.

Diabetes Care. 2019 Aug;42(8):1560-1568. doi: 10.2337/dc19-0571. Epub 2019 Jun 4.

PMID:
31167890
50.

Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease.

Anholm C, Kumarathurai P, Jürs A, Pedersen LR, Nielsen OW, Kristiansen OP, Fenger M, Holst JJ, Madsbad S, Sajadieh A, Haugaard SB.

Diabetol Metab Syndr. 2019 May 31;11:42. doi: 10.1186/s13098-019-0438-6. eCollection 2019.

Supplemental Content

Loading ...
Support Center